☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - February 2016

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Fulvestrant (Faslodex®) has been accepted for use in he treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen. This is a re-submission assessed under the end of life process and takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of fulvestrant. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Guanfacine (Intuniv®) has been accepted for use in the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.

Ulipristal (Esmya®) has been accepted for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - February 2016' by emailShare 'SMC Update - February 2016' on FacebookShare 'SMC Update - February 2016' on TwitterShare 'SMC Update - February 2016' on LinkedInShare 'SMC Update - February 2016' on reddit


No Comments to “SMC Update - February 2016”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.